Treatment of double-refractory multiple myeloma
In most publications on relapsed and refractory multiple myeloma, the term double-refractory refers to the loss of response to lenalidomide and proteasome inhibitors. The prognosis in the case of double-refractory multiple myeloma is poor. Usually, these are severely pretreated patients who have acc...
Saved in:
| Main Author: | S. V. Semochkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-09-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01) -
Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01) -
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01) -
Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01) -
PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)